Ascletis presented phase iii study results of first-in-class fasn inhibitor denifanstat (asc40) for acne treatment in the late breaking news sessions of the european academy of dermatology and venereology (eadv) congress 2025

--denifanstat (asc40) met all primary, key secondary and secondary efficacy endpoints (itt analysis) and significantly improved moderate-to-severe acne compared with placebo. --denifanstat (asc40) demonstrated a favorable safety and tolerability profile.
ASC Ratings Summary
ASC Quant Ranking